157 related articles for article (PubMed ID: 36826137)
1. Understanding Characteristics, Treatment Patterns, and Clinical Outcomes for Individuals with Advanced or Recurrent Endometrial Cancer in Alberta, Canada: A Retrospective, Population-Based Cohort Study.
Martins D; O'Sullivan DE; Boyne DJ; Cheung WY; Allonby O; Habash M; Brenner DR; Riemer J; McGee J
Curr Oncol; 2023 Feb; 30(2):2277-2289. PubMed ID: 36826137
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment of German patients with recurrent and advanced endometrial cancer with a post-platinum treatment: a retrospective claims data analysis.
Mevius A; Karl F; Wacker M; Welte R; Krenzer S; Link T; Maywald U; Wilke T
J Cancer Res Clin Oncol; 2023 May; 149(5):1929-1939. PubMed ID: 35840862
[TBL] [Abstract][Full Text] [Related]
3. Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States.
Liu J; Emond B; Maiese EM; Lafeuille MH; Lefebvre P; Ghelerter I; Wu C; Hurteau JA; Thaker PH
Curr Med Res Opin; 2022 Nov; 38(11):1935-1945. PubMed ID: 35975577
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns and clinical outcomes from a retrospective chart review study of patients with recurrent or advanced endometrial cancer who progressed following prior systemic therapy in Europe.
Zhang J; Kelkar SS; Prabhu VS; Qiao Y; Grall V; Miles N; Marth C
BMJ Open; 2024 Apr; 14(4):e079447. PubMed ID: 38569701
[TBL] [Abstract][Full Text] [Related]
5. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study.
Nagao S; Nishio S; Michimae H; Tanabe H; Okada S; Otsuki T; Tanioka M; Fujiwara K; Suzuki M; Kigawa J
Gynecol Oncol; 2013 Dec; 131(3):567-73. PubMed ID: 24076450
[TBL] [Abstract][Full Text] [Related]
6. Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis.
Heffernan K; Nikitas FS; Shukla U; Camejo HS; Knott C
Gynecol Oncol; 2022 Aug; 166(2):317-325. PubMed ID: 35752507
[TBL] [Abstract][Full Text] [Related]
7. What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.
Nagao S; Nishio S; Okada S; Otsuki T; Fujiwara K; Tanabe H; Takano M; Hasumi Y; Takei Y; Hasegawa T; Matsumoto T; Fujiwara K; Takekuma M; Nakamura K; Shimada M; Suzuki M; Kigawa J
Cancer Chemother Pharmacol; 2015 Aug; 76(2):335-42. PubMed ID: 26092322
[TBL] [Abstract][Full Text] [Related]
8. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
[TBL] [Abstract][Full Text] [Related]
9. Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records.
Monk BJ; Smith G; Lima J; Long GH; Alam N; Nakamura H; Meulendijks D; Ghiorghiu D; Banerjee S
Gynecol Oncol; 2022 Feb; 164(2):325-332. PubMed ID: 34952707
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns and Outcomes Among Patients With Advanced or Recurrent Endometrial Cancer Initiating First-Line Therapy in the United States.
Coleman RL; Garside J; Hurteau J; Nguyen J; Kobayashi M
J Health Econ Outcomes Res; 2023; 10(2):82-90. PubMed ID: 37905183
[No Abstract] [Full Text] [Related]
12. Importance of platinum-free interval in second-line chemotherapy for advanced or recurrent endometrial cancer.
Matoda M; Omatsu K; Yamamoto A; Nomura H; Tanigawa T; Kawamata Y; Kato K; Umayahara K; Takeshima N
Eur J Gynaecol Oncol; 2014; 35(3):224-9. PubMed ID: 24984532
[TBL] [Abstract][Full Text] [Related]
13. Temsirolimus in women with platinum-refractory/resistant ovarian cancer or advanced/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8).
Emons G; Kurzeder C; Schmalfeldt B; Neuser P; de Gregorio N; Pfisterer J; Park-Simon TW; Mahner S; Schröder W; Lück HJ; Heubner ML; Hanker L; Thiel F; Hilpert F
Gynecol Oncol; 2016 Mar; 140(3):450-6. PubMed ID: 26731724
[TBL] [Abstract][Full Text] [Related]
14. Retention of platinum sensitivity till late stages of tumour progression may imply improved prognosis of oesophageal and gastric cancers.
Hingorani M; Dixit S; Roy R; Maraveyas A
Oncol Res Treat; 2015; 38(1-2):28-34. PubMed ID: 25634795
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.
Humber CE; Tierney JF; Symonds RP; Collingwood M; Kirwan J; Williams C; Green JA
Ann Oncol; 2007 Mar; 18(3):409-20. PubMed ID: 17150999
[TBL] [Abstract][Full Text] [Related]
16. Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.
Carroll R; Bortolini M; Calleja A; Munro R; Kong S; Daumont MJ; Penrod JR; Lakhdari K; Lacoin L; Cheung WY
BMC Cancer; 2022 Mar; 22(1):255. PubMed ID: 35264135
[TBL] [Abstract][Full Text] [Related]
17. Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma.
Colomba E; Alexandre J; Le Teuff G; Genestie C; Coupez D; Coquard IR; Brachet PE; de Percin S; Sajous C; Fabbro M; Delanoy N; Joly F; Frenel JS; Pautier P; Leary A
Gynecol Oncol; 2023 Feb; 169():78-84. PubMed ID: 36521352
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma.
Rose PG; Ali S; Moslemi-Kebria M; Simpkins F
Int J Gynecol Cancer; 2017 Mar; 27(3):452-458. PubMed ID: 28187088
[TBL] [Abstract][Full Text] [Related]
19. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
20. Systemic Treatment Patterns With Advanced or Recurrent Non-small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study.
Wang F; Mishina S; Takai S; Le TK; Ochi K; Funato K; Matsuoka S; Ohe Y
Clin Ther; 2017 Jun; 39(6):1146-1160. PubMed ID: 28527959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
